APG-1387
- Generic Name
- APG-1387
- Drug Type
- Small Molecule
- Chemical Formula
- C60H72N10O10S2
- CAS Number
- 1570231-89-8
- Unique Ingredient Identifier
- E53VN70K2X
- Background
APG-1387 is under investigation in clinical trial NCT04568265 (A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B).
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04643405
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
- Conditions
- Chronic Hep BHBVHepatitis B
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04568265
- Locations
- 🇨🇳
Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04284488
- Locations
- 🇨🇳
Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Affiliated Hospital OF Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Foshan First People's Hospital, Foshan, Guangdong, China
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03585322
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Conditions
- Advanced Solid Tumors or Hematologic Malignancies
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03386526
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.